GlaxoSmithKline starts next phase of US sales reps compensation program

5 July 2011

The US subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has implemented the next phase of its new incentive compensation program for professional sales representatives with the introduction of a new performance evaluation methodology and process.

In January 2011, GSK eliminated individual sales goals as part of the company's incentive compensation program for sales professionals who work directly with health care professionals. Beginning July 1, GSK is putting in place a new method for evaluating sales professionals' performance and bonus in alignment with the company's values of transparency, respect for people, integrity and focus on the patient.

Individual sales targets replaced

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK